-
11.发明申请公开(公告)号：US20140220057A1
公开(公告)日：2014-08-07
申请号：US14166950
申请日：2014-01-29
Applicant: OSAKA UNIVERSITY , NITTO DENKO CORPORATION
Inventor： Katsuyuki OKUBO , Yoshiki MAEDA , Arimichi OKAZAKI , Daisuke ASARI , Takuya SHISHIDO , Mitsuhiko HORI , Haruo SUGIYAMA
IPC: A61K9/00 , A61K38/10 , A61K31/437 , A61K31/045 , A61K31/513 , A61K31/739 , A61K31/716 , A61K31/451 , A61K31/728 , A61K39/00 , A61K31/708
CPC classification number: A61K9/0014 , A61K31/045 , A61K31/437 , A61K31/451 , A61K31/513 , A61K31/708 , A61K31/716 , A61K31/728 , A61K31/739 , A61K38/10 , A61K39/0011 , A61K2039/54
Abstract: The present invention provides a cancer vaccine composition for transdermal administration for cellular immunity induction, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a pharmacologically acceptable acid as a first cellular immunity induction promoter, or a pharmacologically acceptable salt thereof.
Abstract translation: 本发明提供了一种用于细胞免疫诱导的透皮给药的癌症疫苗组合物，其包含（i）WT1肽和/或修饰的WT1肽; 和（ii）药理学上可接受的酸作为第一细胞免疫诱导启动子或其药理学上可接受的盐。
-
公开(公告)号：US20160228540A1
公开(公告)日：2016-08-11
申请号：US14916721
申请日：2014-10-02
Applicant: NITTO DENKO CORPORATION
Inventor： Eiji KIYOTOH , Mitsuhiko HORI , Katsuyuki OKUBO , Daisuke ASARI , Arimichi OKAZAKI , Masahiro FUKASAKA , Kyohei MATSUSHITA
IPC: A61K39/39 , A61K39/09 , A61K39/12 , A61K39/15 , A61K39/145 , A61K39/125 , A61K39/165 , A61K39/08 , A61K39/25 , A61K39/205 , A61K39/00 , A61K39/13
CPC classification number: A61K39/39 , A61K39/00 , A61K39/0011 , A61K39/08 , A61K39/092 , A61K39/12 , A61K39/125 , A61K39/13 , A61K39/145 , A61K39/15 , A61K39/165 , A61K39/205 , A61K39/25 , A61K2039/5252 , A61K2039/5254 , A61K2039/543 , A61K2039/55572 , A61K2039/575 , C12N2710/16734 , C12N2710/20034 , C12N2720/12334 , C12N2760/18434 , C12N2760/18734 , C12N2760/20134 , C12N2770/24134 , C12N2770/32434 , C12N2770/32634 , C12N2770/36234
Abstract: The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively. The present invention provides a nasal mucosal vaccine composition to be administered to a human or animal nasal mucous membrane, the nasal mucosal vaccine composition containing at least one antigen excluding antigens derived from influenza viruses; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.
Abstract translation: 本发明提供一种鼻粘膜疫苗组合物，其是安全的，可用作感染性疾病或癌症的预防或治疗剂，并且能够有效地诱导全身免疫应答和粘膜免疫应答。 本发明提供了向人或动物鼻粘膜施用的鼻粘膜疫苗组合物，所述鼻粘膜疫苗组合物含有至少一种除了源自流感病毒的抗原之外的抗原; 并且作为佐剂，衍生自选自沙雷氏菌属（Salratia），莱克氏菌属（Leclercia），R，属（Rahnella），酸性d螨属（Acidicaldus），酸性，螨属（Acidical il ium，，，era era era era era era era，，，，，，，，Acid Acid Acid Acid as as，As As As ia ia ia ia ia C occus occus occus occus occus，，，ia ia，，，，，，，，，，， （Leahibacter），红球菌属（Myocosococcus），梭状芽孢杆菌属，微球菌属，黄杆菌属，泛菌属，醋杆菌属，发酵单胞菌属，黄单胞菌属，蓝假丝酵母属，蓝假丝酵母属，蓝假丝酵母属， 和肠杆菌属或其盐。
-
公开(公告)号：US20160213773A1
公开(公告)日：2016-07-28
申请号：US14917077
申请日：2014-10-02
Applicant: NITTO DENKO CORPORATION
Inventor： Masahiro FUKASAKA , Mitsuhiko HORI , Katsuyuki OKUBO , Daisuke ASARI , Arimichi OKAZAKI , Eiji KIYOTOH , Kyohei MATSUSHITA
CPC classification number: A61K39/39 , A61K39/00 , A61K39/0005 , A61K39/092 , A61K39/12 , A61K39/13 , A61K39/145 , A61K39/15 , A61K2039/52 , A61K2039/525 , A61K2039/541 , A61K2039/542 , A61K2039/543 , A61K2039/544 , A61K2039/55572 , C12N7/00 , C12N2710/20034 , C12N2720/12334 , C12N2760/16034 , C12N2770/32634
Abstract: The present invention aims at providing a vaccine composition capable of being administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is safe, useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and capable of effectively inducing the systemic immune response and mucosal immune response. The present invention provides a mucosal vaccine composition to be administered to at least one mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, the mucosal vaccine composition containing: at least one antigen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof, wherein a mass ratio between the adjuvant and the antigen (total mass of the adjuvant/total mass of the antigen) is 0.002 to 500.
-
公开(公告)号：US20140220100A1
公开(公告)日：2014-08-07
申请号：US14166952
申请日：2014-01-29
Applicant: NITTO DENKO CORPORATION
Inventor： Katsuyuki OKUBO , Yoshiki MAEDA , Takuya SHISHIDO , Daisuke ASARI , Arimichi OKAZAKI , Kyohei MATSUSHITA , Wenjing LI , Mitsuhiko HORI , Haruo SUGIYAMA
IPC: A61K39/00
CPC classification number: A61K39/0005 , A61K39/0011 , A61K2039/54
Abstract: The invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity comprising (i) HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide; and (ii) a first cellular immunity induction promoter.
Abstract translation: 本发明提供了用于诱导细胞免疫的透皮给药的癌症疫苗组合物，其包含（i）HER2 / neu E75肽和/或经修饰的HER2 / neu E75肽; 和（ii）第一细胞免疫诱导启动子。
-
公开(公告)号：US20140220058A1
公开(公告)日：2014-08-07
申请号：US14166959
申请日：2014-01-29
Applicant: NITTO DENKO CORPORATION
Inventor： Yoshiki MAEDA , Katsuyuki OKUBO , Daisuke ASARI , Arimichi OKAZAKI , Takuya SHISHIDO , Kyohei MATSUSHITA , Wenjing LI , Mitsuhiko HORI , Haruo SUGIYAMA
IPC: A61K9/00 , A61K31/739 , A61K31/4745 , A61K39/00 , A61K38/10
CPC classification number: A61K9/0014 , A61K9/006 , A61K31/4745 , A61K31/739 , A61K38/10 , A61K39/0011 , A61K39/12 , A61K2039/54 , A61K2039/541 , A61K2039/55511 , A61K2039/55516 , A61K2039/55572 , C12N2770/24234
Abstract: The invention provides a vaccine composition for transdermal or transmucosal administration for inducing cellular immunity, comprising (i) an antigen; and (ii) a pharmacologically acceptable acid or a pharmacologically acceptable salt thereof as a first cellular immunity induction promoter.
Abstract translation: 本发明提供了用于诱导细胞免疫的透皮或经粘膜给药的疫苗组合物，其包含（i）抗原; 和（ii）药理学上可接受的酸或其药理学上可接受的盐作为第一细胞免疫诱导启动子。
-
Patent Agency Ranking
公开(公告)号：US20170246287A1
公开(公告)日：2017-08-31
申请号：US15337644
申请日：2016-10-28
Applicant: NITTO DENKO CORPORATION
Inventor： Takuya SHISHIDO , Katsuyuki OKUBO , Daisuke ASARI , Arimichi OKAZAKI , Yoshiki MAEDA , Kyohei MATSUSHITA , Wenjing LI , Mitsuhiko HORI , Haruo SUGIYAMA
CPC classification number: A61K39/12 , A61K9/0014 , A61K9/06 , A61K9/7084 , A61K39/0011 , A61K39/39 , A61K47/32 , A61K47/34 , A61K2039/54 , A61K2039/55583
Abstract: Disclosed is a vaccine composition for transdermal administration to induce cellular immunity, comprising an antigen, wherein Th1 cell ratio in a model animal for immunological evaluation that received the composition is 10% or more.
-
公开(公告)号：US20170216431A1
公开(公告)日：2017-08-03
申请号：US15514868
申请日：2015-10-01
Applicant: NITTO DENKO CORPORATION
Inventor： Takuya SHISHIDO , Daisuke ASARI , Kyohei MATSUSHITA , Katsuyuki OKUBO , Mitsuhiko HORI
Abstract: The present invention provides a vaccine pharmaceutical composition for transdermal administration which is safe, usable as a prophylactic or therapeutic agent for cancer or infectious diseases, and capable of safely and effectively inducing a systemic immune response. It can be administered to a human or animal skin, the vaccine pharmaceutical composition including: a lipopolysaccharide or its salt derived from at least one gram-negative bacterium such as Serratia, Lelercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, as an immunostimulant; and at least one antigen, the vaccine pharmaceutical composition having a mass ratio between the immunostimulant and the antigen, the total mass of the immunostimulant/the total mass of the antigen, of 0.002 to 500.
-
18.发明申请COMPOSITION FOR ACCELERATING PENETRATION THROUGH SKIN, PREPARATION FOR TRANSDERMAL ADMINISTRATION, AND SKIN PATCH PREPARATION 审中-公开通过皮肤加速穿透的组合物，用于超导管理的准备和皮肤配制公开(公告)号：US20170007703A1
公开(公告)日：2017-01-12
申请号：US15113275
申请日：2015-01-28
Applicant: NITTO DENKO CORPORATION
Inventor： Kyohei MATSUSHITA , Yoshiki MAEDA , Wenjing LI , Katsuyuki OKUBO , Mitsuhiko HORI
IPC: A61K47/22 , A61K31/616 , A61K38/45 , A61K31/192 , A61K9/00 , A61K9/70
CPC classification number: A61K47/22 , A61K9/0014 , A61K9/7053 , A61K31/192 , A61K31/352 , A61K31/366 , A61K31/616 , A61K38/45 , A61K47/08 , C12Y207/10001 , A61K2300/00
Abstract: The present invention provides a skin penetration-accelerating composition that eliminates the need for forming a drug into a particle structure and dramatically improves the skin penetration properties of a drug without breaking the skin tissue. The present invention also provides a preparation for transdermal administration containing the skin penetration-accelerating composition and a patch preparation containing the skin penetration-accelerating composition. The present invention provides a skin penetration-accelerating composition containing a flavonoid compound and a surfactant and used for accelerating skin penetration of a drug.
Abstract translation: 本发明提供了一种皮肤渗透促进组合物，其消除了将药物形成颗粒结构的需要，并且显着改善药物的皮肤渗透性而不破坏皮肤组织。 本发明还提供了含有皮肤渗透促进组合物和含有皮肤渗透促进组合物的贴剂的透皮给药制剂。 本发明提供含有类黄酮化合物和表面活性剂的皮肤渗透促进组合物，用于加速药物的皮肤渗透。
-
公开(公告)号：US20160287697A1
公开(公告)日：2016-10-06
申请号：US14916807
申请日：2014-10-02
Applicant: NITTO DENKO CORPORATION
Inventor： Kyohei MATSUSHITA , Masahiro FUKASAKA , Arimichi OKAZAKI , Eiji KIYOTOH , Katsuyuki OKUBO , Daisuke ASARI , Mitsuhiko HORI
CPC classification number: A61K39/39 , A61K9/0019 , A61K39/00 , A61K2039/55572
Abstract: The present invention aims at providing an injectable vaccine composition that is safe, useful as a prophylactic or therapeutic agent for cancers or infectious diseases, and capable of inducing the systemic immune response safely and effectively. The present invention is an injectable vaccine composition to be administered by injection to a human being or an animal, containing: at least one antigen, and as an adjuvant, a lipopolysaccharide derived from at least one gram negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.
Abstract translation: 本发明的目的在于提供一种安全有效的可用作癌症或感染性疾病的预防或治疗剂并且能够安全有效地诱导全身免疫应答的可注射疫苗组合物。 本发明是通过注射给人或动物施用的可注射疫苗组合物，其包含至少一种抗原和佐剂，衍生自至少一种革兰氏阴性细菌的脂多糖，所述至少一种阴性细菌选自沙雷氏菌属 ，Leclercia，Rahnella，Acidicaldus，Acidiphilium，Acidisphaera，Acidocella，Acidomonas，Asaia，Belnapia，Craurococcus，Gluconacetobacter，Gluconobacter，Kozakia，Leahibacter，Muricoccus，Neoasaia，Oleomonas，Paracraurococcus，Rhodopila，Roseococcus，Rubritepida，Saccharibacter，Stella，Swaminathania，Teichococcus ，Zavarzinia，假单胞菌属，无色杆菌属，芽孢杆菌属，甲烷球菌属，甲烷球菌属，梭菌属，微球菌属，黄杆菌属，泛菌属，醋杆菌属，发酵单胞菌属，黄单胞菌属，肠杆菌属或其盐。
-
公开(公告)号：US20140234377A1
公开(公告)日：2014-08-21
申请号：US14166945
申请日：2014-01-29
Applicant: NITTO DENKO CORPORATION
Inventor： Arimichi OKAZAKI , Kyohei MATSUSHITA , Daisuke ASARI , Takuya SHISHIDO , Yoshiki MAEDA , Katsuyuki OKUBO , Wenjing LI , Mitsuhiko HORI , Haruo SUGIYAMA
IPC: A61K39/00
CPC classification number: A61K39/0011 , A61K39/39 , A61K2039/542 , A61K2039/55511 , A61K2039/55516 , A61K2039/55561 , A61K2039/55566 , A61K2039/55583 , A61K2039/572
Abstract: The present invention provides a vaccine composition which comprises a cellular immunity induction promoter universally usable against various antigens in cellular immunity induction by mucosal administration of the antigen and exerts a high cellular immunity inducing effect by mucosal administration. The present invention provides a vaccine composition for mucosal administration to induce cellular immunity, comprising: (i) an antigen; and (ii) one or more cellular immunity induction promoters selected from the group consisting of a TLR ligand, a cyclic dinucleotide, a helper peptide and an immunomodulatory small molecule drug.
Abstract translation: 本发明提供一种疫苗组合物，其包含通过粘膜施用抗原而在细胞免疫诱导中抵抗各种抗原通用的细胞免疫诱导启动子，并通过粘膜施用发挥高细胞免疫诱导作用。 本发明提供了用于诱导细胞免疫的粘膜给药用疫苗组合物，其包含：（i）抗原; 和（ii）选自TLR配体，环二核苷酸，辅助肽和免疫调节小分子药物的一种或多种细胞免疫诱导启动子。
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.02 seconds)
